Neurogene Q3 2026 Results: Net Loss of $29M, Loss Widens
Neurogene Inc. reported a net loss of $94.4 million for the nine months ended September 30, 2026, driven by increased R&D expenses for its Rett syndrome clinical programs. The company significantly strengthened its liquidity through a July 2026 public offering and at-the-market sales, ending the period with $362.7 million in total current assets.
- Key figure
- Net loss $29M